Hemorrhagic Cardiac Tamponade Research Articles

Imaging-Guided Percutaneous Endovascular Biopsy Applied in Patients with Pulmonary Artery Masses: A Review.

Pulmonary artery (PA) masses are rare. Distinguishing PA tumours from embolism is sometimes difficult, and surgical biopsy is expensive and risky. We aimed to evaluate the efficacy of imaging-guided percutaneous endovascular biopsy (PEB) for obtaining tissues for histological diagnosis. We searched Cochrane, Medline, Embase, and Web of Science for PEB trials involving patients with PA masses, published from the inception of the database until August 2023. We retrospectively reviewed 33 studies including 87 patients (median age 55 ± 69.3years, 44 men) with PA masses who underwent a total of 110 PEBs. Of these patients, 34.5% (n = 38) underwent PEB-catheter aspiration (PEB-CA), 50.9% (n = 56) underwent PEB-forceps biopsy (PEB-FB) and 2.7% (n = 3) underwent PEB-directional atherectomy (PEB-DA). The most common histological aetiology of PA masses was mesenchymal tumours (n = 67, 75.9%). Tumour embolism (n = 6, 6.9%) and pulmonary embolism (n = 3, 3.4%) were the second and third most common types of PA masses, respectively. The technical success rates of PEB-CA, PEB-FB and PEB-DA were 92.1%, 94.6% and 100% (p = 0.796), respectively. Histopathological analysis provided clinical diagnostic success rates of 44.7%, 85.7% and 100% for PEB-CA, PEB-FB and PEB-DA (p < 0.001), respectively. In pairwise comparison, PEB-FB had a higher success rate in pathological diagnosis than PEB-CA (p = 0.000). Apart from one patient suffering from haemorrhagic cardiac tamponade, no other complications occurred. Imaging-guided PEB is a safe and effective technique for the early pathological diagnosis of PA masses.

FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATION

Introduction: A frontline tailored treatment for indolent clinical forms of mantle cell lymphoma (MCL) with ibrutinib in combination with rituximab was evaluated. A high rate of complete remissions (CR) with undetectable minimal residual disease (MRD) was reported, with predictable toxicity (Giné, JCO 2022). We herein present an updated analysis focusing in the data of treatment discontinuation. Methods: This was an open-label, phase II trial conducted in 14 Spanish GELTAMO sites (NCT02682641). Centralized histology, PET-CT review, MRD studies (qPCR and NGS in peripheral blood) and biological studies were conducted. Previously untreated MCL patients with indolent clinical forms were eligible according to the following criteria: no symptoms attributable to MCL, ECOG 0–1, stable disease without therapy need for at least 3 months, non-blastoid variants, Ki-67 <30% and largest tumor diameter ≤3 cm. Both leukemic non-nodal and nodal forms were acceptable. Patients received ibrutinib 560 mg daily and a total of 8 doses of rituximab 375 mg/m2 (4 weekly doses during the first 28-day cycle, followed by day 1 of cycles 3, 5, 7 and 9). Ibrutinib could be discontinued after 2 years of treatment in case of sustained undetectable MRD. Results: Fifty patients (Male 66%; median age 65 years) were enrolled in the study (June 2016 to December 2019, data cut-off 18 October 2022, median follow-up 54 months and next cut-off is planned in March 2023). The overall response (OR) and CR rates at 12 months of treatment were 84% and 80%, respectively (including 4 early discontinuations). Undetectable MRD was reached in 40 (87%) of 46 evaluable cases (sensitivity 10−5). After 24 months, 42 of 44 patients were in response, with OR and CR rates of 86% and 84%, respectively. Undetectable MRD was observed in 35 (80%) of 44 cases. Thirty-two patients discontinued ibrutinib as per protocol (64% of initial series). Twelve patients continued on ibrutinib. Median time on ibrutinib treatment was 29 months (1.7–51+ months). The median duration of undetectable MRD, achieved in 41 cases, was 60 months (95% CI: 29–92), and has not been reached in the 32 cases that stopped ibrutinib as per protocol. Six patients progressed from the disease between 12 and 72 months of follow-up and three of them eventually died of disease progression. Overall, PFS and OS at 48 months were 86% (95% CI: 75–96) and 88% (95% CI: 79–98), respectively. At current follow-up, 6 patients remain on treatment, and up to 13 patients discontinued ibrutinib because of adverse events, including 7 associated to ibrutinib with a hemorrhagic cardiac tamponade being the most severe. Five secondary neoplasms in 4 patients have been reported. Whole-genome sequencing of paired tumor/normal samples from 34 patients was obtained and will be presented. The research was funded by: The funding for the IMCL-2015 was obtained through unrestricted Janssen Clinical Investigator-Initiated Study (IIS) Research Support Keywords: aggressive B-cell non-Hodgkin lymphoma, molecular targeted therapies Conflicts of interests pertinent to the abstract E. Giné Consultant or advisory role: Gilead, Milteny Honoraria: Janssen, Genmab, Gilead Research funding: Janssen Educational grants: Janssen A. Medina-Herrera Research funding: Janssen Educational grants: Invivoscribe F. de la Cruz Honoraria: Roche, Takeda, Eusa Pharma, Abbvie, Janssen, Beigene, Kiowa Kirin, Astrazeneca and Gilead J. López Jiménez Honoraria: Roche, Abbvie, Janssen and Gilead Research funding: Roche Educational grants: Gilead, Janssen, Abbvie A. Martín García- Sancho Consultant or advisory role: Roche, Celgene/BMS, Morphosys, Kyowa Kirin, Clinigen, Eusa Pharma, Novartis, Gilead, Servier, Incyte Honoraria: Roche, Celgene, Janssen, Servier, Gilead Research funding: Janssen Educational grants: Roche, Servier, Celgene, Janssen, KernPharma M. J. Terol Research funding: Gilead Educational grants: Janssen, Gilead/Kite, Roche, Abbvie A. de la Fuente Honoraria: Abbvie, Astellas Pharma, BMS, incite, JazzPharma, Novartis, Roche and Pfizer Research funding: Janssen, Novartis Educational grants: Abbvie, Astellas Pharma, BMS, Incyte, Janssen, JazzPharma, Mundipharma, Roche, Pfizer A. Marín Niebla Consultant or advisory role: Janssen, Gilead, Kiowa Kirin, Takeda, Beigene Honoraria: Gilead/Kite, Janssen, Genmab Educational grants: Takeda, Janssen, Kiowa Kirin T. J. González López Honoraria: Novartis, Amgen, Sobi, Grifols and Mome Research funding: Novartis, Amgen X. Setoain Honoraria: Roche, Gilead, General Electric Educational grants: General Electric, Takeda R. García Sanz Honoraria: Janssen, Beigene Research funding: Janssen A. López Guillermo Consultant or advisory role: Roche, Gilead/Kite, Celgene, Novartis, Janssen, Abbie, Spectrum Honoraria: Roche, Celgene, Gilead/Kite Research funding: Roche, Celgene, Gilead

Clinical case of SARS-CoV-2 infection, complicated by the viral pneumonia, the left ventricular wall rupture and the hemorrhagic cardiac tamponade

Clinical case of SARS-CoV-2 infection, complicated by the viral pneumonia, the left ventricular wall rupture and the hemorrhagic cardiac tamponade

SARS-COV-2-INDUCED COAGULOPATHY DEMONSTRATING HEMORRHAGIC CARDIAC TAMPONADE: A TIGHT SQUEEZE

SARS-COV-2-INDUCED COAGULOPATHY DEMONSTRATING HEMORRHAGIC CARDIAC TAMPONADE: A TIGHT SQUEEZE

Significance of medical intervention for non-traumatic hemorrhagic cardiac tamponade.

The outcomes of patients with cardiac arrest induced by non-traumatic hemorrhagic cardiac tamponade are poor. We retrospectively investigated the significance of medical intervention with pericardiocentesis and/or pericardiotomy for non-traumatic hemorrhagic cardiac tamponade. From January 2013 to April 2021, we retrospectively reviewed the medical charts of all patients with cardiac arrest in a prehospital setting or emergency room due to cardiac tamponade confirmed by an ultrasound examination with or without an invasive procedure (pericardiocentesis and/or pericardiotomy) and computed tomography findings, including those obtained at autopsy imaging. The subjects were divided into two groups: the Intervention (+) group, which included subjects who underwent pericardiocentesis or pericardiotomy, and the Intervention (-) group, which included subjects who did not undergo pericardiocentesis or pericardiotomy. Variables were then compared between the two groups. There were 68 patients with non-traumatic cardiac tamponade. All three survival cases had witnessed collapse, and the initial rhythm was pulseless electrical activity (PEA).There were no statistically significant differences in the sex, age, means of transportation, bystander chest compression, electric shock, or adrenalineor FDP levels between the two groups.However, the number with witnessed collapse, PEA, rupture of the heart;the ratio of obtaining return of spontaneous circulation; and the survival ratio were significantly greater in the Intervention (+) group than in the Intervention (-) group. Based on the results of preliminary study, we hypothesized that invasive medical intervention for patients with cardiac arrest induced by non-traumatic hemorrhagic cardiac tamponade might be useful for obtaining return of spontaneous circulation and a survival outcome, especially for patients with witnessed collapse with PEA as the initial rhythm.

C34. Concomitant Finding of Hemorrhagic Cardiac Tamponade and Venous Thromboembolism as the First Manifestation of Occult Malignancy – A Case Report

Abstract Background Venous thromboembolism (VTE) encompasses pulmonary embolism (PE), and deep vein thrombosis (DVT) is a common complication of cancer. Cancer manifestation in cardiac often secondary from the metastatic process, mostly in the pericardium. These concomitant findings of PE, DVT, and hemorrhagic cardiac tamponade as the first signs of cancer in a young patient is rare. Case Summary A 39-years-old man was referred to the emergency department from secondary hospital with the main complaint of dyspnea that onset abruptly two days before admission and swollen of the entire right leg since one week before. We report concomitant finding of hemorrhagic cardiac tamponade, deep vein thrombosis, and acute pulmonary embolism as initial presentations of occult malignancy. Starting anticoagulant in the hemorrhagic state and finding the primary cancer were problematic and challenging. Discussion The challenge in management, posed by hemorrhagic versus thrombosis state in cancer, prompted us to cautiously deliver the treatment with consideration of benefit over the risk. Primary cancer is not always easy to identify. Comprehensive (re-)evaluation is mandatory.

C34. Concomitant Finding of Hemorrhagic Cardiac Tamponade and Venous Thromboembolism as the First Manifestation of Occult Malignancy – A Case Report

Abstract Background Venous thromboembolism (VTE) encompasses pulmonary embolism (PE), and deep vein thrombosis (DVT) is a common complication of cancer. Cancer manifestation in cardiac often secondary from the metastatic process, mostly in the pericardium. These concomitant findings of PE, DVT, and hemorrhagic cardiac tamponade as the first signs of cancer in a young patient is rare. Case Summary A 39-years-old man was referred to the emergency department from secondary hospital with the main complaint of dyspnea that onset abruptly two days before admission and swollen of the entire right leg since one week before. We report concomitant finding of hemorrhagic cardiac tamponade, deep vein thrombosis, and acute pulmonary embolism as initial presentations of occult malignancy. Starting anticoagulant in the hemorrhagic state and finding the primary cancer were problematic and challenging. Discussion The challenge in management, posed by hemorrhagic versus thrombosis state in cancer, prompted us to cautiously deliver the treatment with consideration of benefit over the risk. Primary cancer is not always easy to identify. Comprehensive (re-)evaluation is mandatory.

Abstract 13722: There Will be Blood: A Cautionary Tale of Triple Therapy

A 54-year-old man with coronary artery disease, chronic kidney disease, atrial flutter, and chronic right internal carotid artery (ICA) occlusion was transferred to our institution for management of cardiogenic shock following an anterior ST-elevation myocardial infarction status post percutaneous coronary intervention of the left main coronary artery (LMCA). He was placed on short-term triple antithrombotic therapy. On the day before discharge, he acutely developed left sided neurological deficits and hypotension. Exam was concerning for a right hemispheric stroke. Labs revealed a creatinine of 2.8 mg/dL, INR of 3.7, and a hemoglobin of 6.6 g/dL (previously 10 g/dL). Prior to sending the patient for brain imaging, we performed a bedside echocardiogram to further evaluate his hypotension. This revealed a large pericardial effusion with tamponade physiology. We suspected hemorrhagic cardiac tamponade secondary to triple antithrombotic therapy. His hypotension initially responded to intravenous fluids and packed red blood cells, resulting in an improved neurologic exam and supporting our hypothesis that his deficits represented right cerebral hemispheric hypoperfusion in the setting of a known right ICA occlusion and tamponade. Pericardiocentesis was initially deferred, as the risk of bleeding appeared prohibitive without reversal of apixaban and his coagulopathy, and these measures would subject the patient to a significant risk of thrombosis (e.g. LMCA stent thrombosis). Unfortunately, the patient developed progressive shock. After careful informed consent, we proceeded with high-risk pericardiocentesis involving pre-procedural reversal of apixaban with andexanet alfa and successful evacuation of 300 ml of hemorrhagic fluid. The pericardial pressure improved from 24 mmHg to 4 mmHg with complete resolution of the patient’s shock and neurological deficits. Our case demonstrates the risks associated with triple antithrombotic therapy as well as the nuanced clinical decision-making and risk-benefit assessment required when considering the use of anticoagulant reversal agents to prevent bleeding complications in the context of recent ischemic events and the need for urgent invasive procedures.

AML-212: Combination of Venetoclax and Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: Single-Center Clinical Experience

Context We report patients with R/R-AML who were treated with venetoclax and hypomethylating agent (HMA). Objective Venetoclax is an oral selective inhibitor of antiapoptotic protein BCL-2, which is overexpressed in AML and associated with poor prognosis. Venetoclax is used in combination with HMA for newly diagnosed AML patients who are elderly or unfit for standard intensive induction/salvage therapies. Design We analyzed 4 R/R-AML patients who were treated with venetoclax and HMA, retrospectively. Patients Case 1: A 45-year-old male patient developed multiorgan failure (MOF) after 3+7 induction chemotherapy. He was followed up in intensive care unit (ICU) for 17 days. He achieved complete remission (CR) after induction. He received two cycles of 5-azacytidine for maintenance. He relapsed and had decitabine and venetoclax. He achieved CR after two cycles. He relapsed in follow-up and passed away from sepsis. Case 2: A 45-year-old male patient diagnosed with MDS transformed AML. After 3+7 induction chemotherapy, he had recurrent pneumonia and a breast abscess. After two cycles of azacytidine, he had still refractory disease. He was shifted to decitabine and venetoclax. He required ICU for gastrointestinal bleeding and passed away. Case 3: A 63-year-old female had a serious anal abscess after 3+7 induction chemotherapy. She had persistent MRD after 4 cycles of decitabine, she received 4 cycles of azacytidine and venetoclax. She remains in CR for 10 months of venetoclax/azacytidine. Case 4: 66-year-old male, after 3+7 induction and 4 consolidation cycles of HDAC, he was in CR. Two years later, he relapsed and achieved CR with FLAG; then, he underwent allo-SCT. Six years later, his disease relapsed and he had 6 cycles of azacytidine again. He had CR but relapsed 1 year later. Two cycles of venetoclax and azacytidine were administered. He had recurrent pneumonia and passed away from hemorrhagic cardiac tamponade. Results Three patients showed no response and developed fatal infections with MOF. Only one patient had CR and she has been treated with venetoclax/5-azacytidine for 10 months. Conclusion These outcomes indicate the feasibility of using venetoclax combination with hypomethylating agents. This approach is a salvage option for preventing the use of standard chemotherapy.

Delayed cardiac tamponade following catheter ablation of frequent premature ventricular complexes: a case report

BackgroundCardiac tamponade is a potentially fatal complication after catheter ablation of ventricular arrhythmias. It often happens during or shortly after the procedure and needs urgent treatment. Here, we present a very incredible case about delayed cardiac tamponade after ablation of premature ventricular complexes.Case presentationA 66-year-old woman who underwent successful catheter ablation of right ventricular outflow tract origin premature ventricular complexes. Nineteen days after ablation, the patient experienced sudden syncope. Upon arriving at our hospital, she was “confused and shock”. Transthoracic echocardiography revealed hemorrhagic cardiac tamponade, which was considered due to a delayed tiny perforation in the heart induced by the previous ablation. Following an emergent pericardiocentesis to drain a 200 mL hemorrhagic effusion, the patient’s hemodynamics improved significantly. The patient was discharged after a 2-week hospitalization for investigating other probable causes with negative results. No signs of pericardial effusion recurred in a follow-up time of 12 months.ConclusionThis case report demonstrated, for the first time, that very late post-procedural cardiac tamponade might occur after catheter ablation of ventricular arrhythmias, even without antithrombotic treatment.

Retrospective analysis of 147 cases of reoperations in congenital heart disease

To analyse the clinical data of reoperations in congenital heart disease and discuss the management strategy of reoperation for congenital heart disease. Methods: We retrospectively studied the clinical data for patients underwent reoperation in congenital heart disease in Cardiovascular Surgery, Second Xiangya Hospital, Central South University from January 2007 to December 2015. Demographic and operative details, in-hospital mortality and major postoperative complications were analysed. Results: A total of 8 647 congenital heart disease surgery procedures were performed, including 147 (1.7%) reoperations. Among the patients, residual septal defect repair (30 cases, 20.4%), planed staged operation (28 cases, 19.0%), and Fontan procedure (20 cases, 13.6%) were the most common kinds of reoperation. In addition, 140 (95%) operations were through repeat sternotomies, 144 (98%) patients underwent operation with cardiopulmonary bypass, and 100 (68%) with cardiac arrest. Cardiopulmonary bypass and aortic cross clamp were maintained for 21-447 (135.5±87.8) minutes and 0-202 (49.9±49.7) minutes. There were 10 in-hospital deaths with a total mortality of 6.8%. The major complications included low cardiac output syndrome (24 cases, 16.3%), renal dysfunction (7 cases, 4.8%), respiratory insufficiency (14 cases, 9.5%), unplanned reoperations for drainage of haemorrhagic cardiac tamponade (4 cases), and delayed sternal closure (2 cases). Conclusion: Repeat sternotomy is the main way of reoperation, but it is not a major risk for operative mortality and morbidity. Improving the management of complex malformation, standardizing the follow-up, choosing the right timing of surgery, and reducing surgical complications will help reduce the risk of reoperation.

Thoracoscopic Fenestration for Hemorrhagic Cardiac Tamponade Induced by Cardiotoxicity of Cyclophosphamide

Abstract Background: Cardiac tamponade is a common occurrence and it has a number of potential causes, including cardiac surgery, malignancy, infection, and pericarditis.1,2 Various approaches have...

Autologous blood reinfusion during iatrogenic acute hemorrhagic cardiac tamponade: Safety and feasibility in a cohort of 30 patients.

Iatrogenic hemorrhagic pericardial tamponade (IHPT) represents a life-threating condition requiring emergency pericardiocentesis. In this clinical context, reinfusion of pericardial blood can stabilize the patient and sustain hemodynamic conditions. We reviewed all cases of IHPT occurred at our hospital over a 10 years span. In all patient autologous blood reinfusion through a femoral vein was performed. In our clinical experience of 30 consecutive patients with hemorrhagic cardiac tamponade, this technique was successful to limit blood transfusions, to prevent further clinical worsening and bridge patients with intractable bleeding, to cardiac surgery. No major adverse reactions were directly related to blood autotransfusion. In the complex clinical scenario of acute tamponade occurring during catheter-based cardiac procedures, autotransfusion of pericardial blood through a femoral vein is safe and effective. It can be a useful trick up the sleeve of the interventional cardiologist.

Focal Myopericarditis as a Rare but Important Differential Diagnosis of Myocardial Infarction; a Case Series.

Distinguishing ST-elevation myocardial infarction (STEMI) differential diagnoses is more challenging. Myopericarditis is one of these differentials that results from viral involvement of myocardium and pericardium of the heart. Myopericarditis in focal form can mimic acute STEMI in its electrocardiogram (ECG) features and elevated cardiac enzymes. Myocarditis patients may face thrombolytic related complications such as intracranial bleeding, myocardial rupture, and hemorrhagic cardiac tamponade. Furthermore, re-administration of streptokinase (a common thrombolytic agent in our country) is banned for at least six months of previous administration; however, it can save patients' lives in emergency conditions such as massive pulmonary embolism. It seems that, when dealing with a young patient presenting to emergency department with acute chest pain and ST segment elevation on ECG, we should consider focal myocarditis as an important but rare differential diagnosis of STEMI. In this report, we describe three cases of focal myocarditis, primarily misdiagnosed as STEMI.

Hemopericardium after Lung Lobectomy

Cardiac tamponade after lung resection is a very rare but life-threatening complication. The present case illustrates another of this uncommon complication, wherein the exact mechanism of injury remained undefined. Hemorrhagic cardiac tamponade occurred few hours after left lower lung lobectomy and re-thoracotomy surprisingly revealed that a left coronary artery branch rupture was the cause.

Spontaneous isolated pericardial tamponade associated with warfarin.

To the Editor, An 83-year-old female patient was admitted to the emergency department with progressive dyspnea and orthopnea for 3 days. She was discharged with warfarin therapy (5 mg per day) due to pulmonary embolism 5 months previously. On admission she was orthopneic and tachypneic. Her arterial blood pressure was 90/60 mmHg and heart rate was 115/min with sinus rhythm. On cardiac auscultation, S1 and S2 intensity were decreased, and pathologic murmur and pericardial friction were not observed. Other physical examination findings were unremarkable. An increased cardio-thoracic ratio was revealed on chest X-ray (Figure 1a). Decreased QRS voltage and sinus tachycardia was evaluated on electrocardiogram. The internalised normalised ratio (INR) level was 8.6 and the prothrombin time was 70 seconds. Haemoglobin was determined to be 11.1 g/dL. The other laboratory findings were normal. An emergency thoracic computed tomography (CT) scan was performed to exclude recurrent pulmonary embolism, and surprisingly showed a massive pericardial effusion (Figure 1b). However, echocardiography revealed severe pericardial effusion that was compressing the right ventricle. Therefore, vitamin K and fresh frozen plasma infusion were administered promptly. As a result, the INR was decreased to 1.4 and 800 mL haemorrhagic fluid was drained percutaneously (P/S) with the apical approach. The patient’s blood pressure, orthopnoea and dyspnoea improved dramatically. There was no other source of bleeding except haemopericardium. Consequently, the cardiac tamponade in our patient, secondary to haemopericardium, was considered to be the result of the incorrect dosage of Warfarin. On control echocardiography, there was no recurrence of pericardial fluid and the patient was discharged on the 5th day. FIG. 1. a, b. Increased cardio-thoracic ratio due to pericardial effusion on chest X-ray (a). CT scan of chest showing large pericardial effusion (see arrow) (b) Cardiac tamponade is a life-threatening emergency condition. It is an acute type of pericardial effusion in which fluid accumulates in the intrapericardial space. This creates a mechanical pressure in the cardiac chambers which disrupts cardiac filling. (1). The common causes of pericardial effusion resulting in tamponade are pericarditis, malignancy, acute myocardial infarction, congestive heart failure, collagen vascular diseases, end stage renal disease, viral and bacterial infections (1). Cardiac tamponade secondary to haemopericardium is rarely seen and occurs with traumatic and non-traumatic causes. Non-traumatic causes are less common and associated with a number of conditions such as malignancy, infection, uraemia or coagulopathy (2). Today, warfarin sodium is still the most commonly used agent for anticoagulant therapy. The risk of spontaneous bleeding in patients using warfarin is less than 10%, whereas the risk of bleeding into the pericardial space is less than 1% (3). Echocardiography, which is the diagnostic test of choice, evaluates the haemodynamic consequences and guides transcutaneous drainage; CT is useful for further workup. These methods are superior to echocardiography for anatomical information, characterisation of the effusion, and providing information about the adjacent structures (2). The primary treatment of pericardial tamponade is pericardiocentesis.. Echocardiography-guided pericardiocentesis has been shown to be a safe and effective method which can be performed at the patient’s bedside (4). Isolated haemopericardium and cardiac tamponade secondary to warfarin are seen very rare. Haemorrhagic cardiac tamponade should be excluded in patients on warfarin with unexplained hypotension and excessive anticoagulation. Close monitoring of INR level is very important in the management of patients, especially in the elderly receiving warfarin treatment (5).

Hemorrhagic Cardiac Tamponade: Rare Complication of Radiofrequency Ablation of Hepatocellular Carcinoma

Local treatment for hepatocellular carcinoma (HCC) has been widely used in clinical practice due to its minimal invasiveness and high rate of cure. Percutaneous radiofrequency ablation (RFA) is widely used because its treatment effectiveness. However, some serious complications can arise from percutaneous RFA. We present here a rare case of hemorrhagic cardiac tamponade secondary to an anterior cardiac vein (right marginal vein) injury during RFA for treatment of HCC.

Haemorrhagic cardiac tamponade: a rare complication of pneumonia

A 78-year-old female presented with a cough and flu-like symptoms of 1-week duration. Examination revealed her to be febrile (38.2°C), hypoxic (oxygen saturation of 87% in room air) and marginally hypotensive (108/50 mmHg). Respiratory examination revealed a dull percussion note, coarse crepitations and bronchial breath sounds at the left base. The heart sounds were noted to be quiet. Investigations showed neutrophilia (10.3 × 109/l), ESR 101 mm/h, CRP 241 mg/l, sodium 122 mmol/l, urea 11.5 mmol/l and creatinine 116 μmol/l. Chest X-ray on admission showed a left basal infiltrate, a flask-shaped heart and left pleural effusion. ECG showed small voltage complexes. …

Hemorrhagic cardiac tamponade and successful pericardiocentesis in a one-day newborn

Pericarditis is an extremely rare disease in the neonatal period and is rapidly fatal if left untreated [1,2]. We report a newborn with large pericardial hemorrhagic effusion with unknown etiology who management with successful pericardiocentesis.A one-day old male newborn was referred our clinics b

Hemorrhagic cardiac tamponade and successful pericardiocentesis in a one‐day newborn

Acta PaediatricaVolume 95, Issue 5 p. 625-626 Hemorrhagic cardiac tamponade and successful pericardiocentesis in a one-day newborn Osman Baspinar, Corresponding Author Osman Baspinar Department of Paediatric Cardiology and Paediatrics, Gaziantep University Faculty of Medicine, Gaziantep, Turkey Osman Baspinar, Gaziantep Üniversitesi, Tip Fakültesi, Pediatri ABD 27310 Gaziantep Turkey. +90 342 360 60 60 +90 342 360 15 52 baspinar@gantep.edu.trSearch for more papers by this authorYilmaz Kor, Yilmaz Kor Department of Paediatric Cardiology and Paediatrics, Gaziantep University Faculty of Medicine, Gaziantep, TurkeySearch for more papers by this authorZiya Bayraktaroglu, Ziya Bayraktaroglu Department of Paediatric Cardiology and Paediatrics, Gaziantep University Faculty of Medicine, Gaziantep, TurkeySearch for more papers by this author Osman Baspinar, Corresponding Author Osman Baspinar Department of Paediatric Cardiology and Paediatrics, Gaziantep University Faculty of Medicine, Gaziantep, Turkey Osman Baspinar, Gaziantep Üniversitesi, Tip Fakültesi, Pediatri ABD 27310 Gaziantep Turkey. +90 342 360 60 60 +90 342 360 15 52 baspinar@gantep.edu.trSearch for more papers by this authorYilmaz Kor, Yilmaz Kor Department of Paediatric Cardiology and Paediatrics, Gaziantep University Faculty of Medicine, Gaziantep, TurkeySearch for more papers by this authorZiya Bayraktaroglu, Ziya Bayraktaroglu Department of Paediatric Cardiology and Paediatrics, Gaziantep University Faculty of Medicine, Gaziantep, TurkeySearch for more papers by this author First published: 02 January 2007 https://doi.org/10.1111/j.1651-2227.2006.tb02297.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume95, Issue5May 2006Pages 625-626 RelatedInformation